STTK
Shattuck Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.72
−1.46%Oct 13, 2026, 12:00 UTC
Shattuck Labs, Inc. announced that it will present two posters at UEG Week 2026 in Barcelona.
Source:Oct 1, 2026, 11:00 UTC
Shattuck Labs appointed Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development, to lead the hidradenitis suppurativa clinical development program.
Source:Oct 1, 2026, 11:00 UTC
Shattuck Labs announced plans to evaluate SL-325 in a Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa, expected to initiate in 2026.
Source:Aug 11, 2026, 00:00 UTC
Shattuck Labs reported financial results for Q2 2026, with zero revenue, a net loss of $15.2 million, and diluted EPS of -$0.12.
Aug 11, 2026, 00:00 UTC
Shattuck Labs received approximately $57.1 million in gross proceeds from the exercise of common stock warrants.
Aug 11, 2026, 00:00 UTC
Shattuck Labs completed an underwritten public offering of common stock and warrants, raising approximately $86.2 million in gross proceeds.
Jun 9, 2026, 20:18 UTC
Shattuck Labs, Inc. commenced a public offering of shares of its common stock and pre-funded warrants.
Jun 9, 2026, 12:00 UTC
Shattuck Labs received notices to exercise approximately 50.6 million common stock warrants from its August 2025 private placement.
Jun 2, 2026, 00:00 UTC
Shattuck Labs elected Taylor Schreiber, Helen M. Boudreau, and Clay Siegall as Class III directors, effective May 28, 2026.